Bcl-2 family inhibitors are designed to restore the apoptotic process by inhibiting the function of anti-apoptotic Bcl-2 proteins. These inhibitors mimic the action of pro-apoptotic proteins, binding to the same pocket on anti-apoptotic proteins, thus displacing and activating pro-apoptotic proteins like Bax and Bak. This leads to the initiation of apoptosis and the subsequent death of cancer cells.
